Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HM 16390

X
Drug Profile

HM 16390

Alternative Names: HM-16390

Latest Information Update: 24 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Interleukin-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Solid tumours

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 14 Apr 2023 Pharmacokinetics, pharmacodynamics, adverse event data from a preclinical trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
  • 10 May 2022 HM 16390 is available for licensing as of 10 May 2022. http://www.hanmi.co.kr/upfile/ces/information/INFORMATION_IR_DATAROOM/90150854/44370777-c124-4fbd-a4d0-57ff62bd610f.pdf
  • 10 May 2022 Preclinical trials in Solid tumours in South Korea (Parenteral) (Hanmi Pharma pipeline, May 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top